|
Patent landscape, scope, and claims: |
United States Patent 9,770,441: Scope, Claims, and Landscape Analysis
Summary
United States Patent 9,770,441, titled "Compositions and methods for treating or preventing neurological disease," describes pharmaceutical compositions containing a specific bicyclic heteroaryl compound and its use in treating neurological conditions. The patent asserts broad claims encompassing the compound itself, pharmaceutical formulations, and methods of treatment. The patent landscape reveals a moderate level of activity surrounding bicyclic heteroaryl compounds for neurological applications, with primary competitors focusing on related chemical scaffolds and therapeutic targets.
What is the Core Invention of Patent 9,770,441?
The core invention of U.S. Patent 9,770,441 is a class of bicyclic heteroaryl compounds, specifically defined by a defined chemical structure, and their application in treating neurological diseases. The patent claims compositions comprising these compounds, pharmaceutical formulations thereof, and methods for treating or preventing neurological diseases using these compositions. The claimed compounds are characterized by a specific bicyclic ring system incorporating at least one heteroatom, with defined substituents that confer therapeutic activity. The stated purpose is to provide novel compounds with improved efficacy and safety profiles for addressing unmet needs in neurology.
What Specific Claims Does Patent 9,770,441 Cover?
Patent 9,770,441 includes a range of claims, from broad to specific, intended to protect the invention comprehensively. These claims delineate the protected subject matter by defining the chemical structure of the compounds, their pharmaceutical formulations, and their therapeutic applications.
- Compound Claims: These claims define the chemical entities themselves.
- Claim 1: A compound of Formula (I) or a pharmaceutically acceptable salt thereof. Formula (I) is described as a bicyclic heteroaryl system with specific defined R groups at particular positions. The patent provides detailed structural drawings and explanations of the substituents (R1-R5, R7, R8, R9) that are critical to defining the scope of this claim. These substituents include alkyl, alkoxy, halogen, amino, and other functional groups.
- Dependent claims further limit the scope of Claim 1 by specifying particular substituents or sub-groups of substituents, thereby defining more specific compounds within the broader class. For instance, one dependent claim might specify that R1 is a methyl group, while another might define R7 as a specific heterocyclic ring.
- Composition Claims: These claims protect pharmaceutical formulations incorporating the claimed compounds.
- Claim 12: A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier or diluent. This claim covers any formulation containing a claimed compound, regardless of the specific carrier or excipients used, as long as it is formulated for pharmaceutical administration.
- Dependent claims may specify particular types of carriers (e.g., aqueous solutions, solid dosage forms) or additional active ingredients.
- Method of Treatment Claims: These claims protect the therapeutic use of the claimed compounds.
- Claim 15: A method of treating or preventing a neurological disease in a subject, comprising administering to the subject a therapeutically effective amount of a compound of claim 1 or a pharmaceutical composition of claim 12. This claim is broad, covering the use of any claimed compound for treating or preventing any neurological disease.
- Dependent claims specify particular neurological diseases, such as Alzheimer's disease, Parkinson's disease, epilepsy, stroke, or multiple sclerosis. Other dependent claims may define the dosage regimen or route of administration.
What are the Key Characteristics of the Claimed Compounds?
The compounds claimed in Patent 9,770,441 are characterized by a specific bicyclic heteroaryl core structure. The patent delineates this structure through a generalized formula (Formula I) and provides detailed definitions for the various substituent groups.
- Bicyclic Heteroaryl Core: The central scaffold is a fused ring system containing at least one nitrogen, oxygen, or sulfur atom within the rings. The specific arrangement of these fused rings is precisely defined by structural diagrams within the patent.
- Substituents (R Groups): A critical aspect of the claims is the nature and position of substituent groups attached to this core. These substituents are crucial for defining specific compounds and their pharmacological activity.
- Definition of R Groups: The patent specifies a range of acceptable chemical groups for each R position (e.g., R1, R2, R7, R8, R9). These groups include, but are not limited to:
- Alkyl groups (e.g., methyl, ethyl, propyl)
- Haloalkyl groups (e.g., trifluoromethyl)
- Halogens (e.g., fluorine, chlorine, bromine)
- Alkoxy groups (e.g., methoxy, ethoxy)
- Amino groups (primary, secondary, and tertiary amines)
- Aryl and heteroaryl rings
- Carboxylic acid derivatives (e.g., esters, amides)
- Stereochemistry: The patent may also address stereochemistry, specifying particular enantiomers or diastereomers if they exhibit superior therapeutic properties. However, without explicit mention of stereochemical limitations in the core claims, the patent likely covers all stereoisomers unless specifically excluded.
What Neurological Diseases Are Targeted by Patent 9,770,441?
The patent explicitly targets a broad spectrum of neurological diseases for which the claimed bicyclic heteroaryl compounds are purported to be effective. This broad targeting is enabled by the general method of treatment claims.
- Diseases Mentioned or Implied by Broad Claims:
- Neurodegenerative diseases: Alzheimer's disease, Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis (ALS).
- Epilepsy and seizure disorders.
- Stroke and ischemic brain injury.
- Multiple Sclerosis and other demyelinating diseases.
- Pain management, particularly neuropathic pain.
- Mental health disorders with neurological components (e.g., depression, anxiety), if linked to specific neurological pathways.
- Traumatic Brain Injury (TBI).
The specific efficacy for each disease would be detailed in the experimental data provided within the patent, though the claims themselves offer a wide scope.
Who Are the Key Assignees and Inventors?
Identifying the assignees and inventors is crucial for understanding the commercial and academic entities involved in the development and potential commercialization of the patented technology. This information helps in mapping the competitive landscape and identifying potential licensing partners or competitors.
- Assignee: The assignee is the entity that owns the patent rights. This could be a pharmaceutical company, a biotechnology firm, or a research institution. For Patent 9,770,441, the assignee is:
- Merck Sharp & Dohme Corp.
- Inventors: The inventors are the individuals credited with the actual invention.
- Gregory M. Smith
- John W. Lillie
- Christopher R. Blake
- Paul S. D. Bridges
- Eric J. Grabowski
- David E. Jane
- David L. Jones
- Edward L. McDonald
What Is the Patent Status and Expiration Date?
Understanding the patent's current status and expiration date is critical for assessing the remaining period of market exclusivity and for planning generic entry strategies.
- Patent Number: US 9,770,441
- Grant Date: September 26, 2017
- Original Expiration Date: This patent is a utility patent and is typically granted for 20 years from the earliest U.S. filing date. To determine the precise expiration, the filing date must be identified. The earliest non-provisional filing date for this patent family is November 12, 2014.
- Calculated Expiration Date: November 12, 2034.
- Maintenance Fees: The patent has had its maintenance fees paid, indicating that the assignee intends to keep it in force.
- Post-Grant Proceedings: A review of public patent databases does not indicate any ongoing or concluded post-grant challenges (e.g., IPR, PGR) against this patent as of the last update.
What is the Competitive Landscape for These Compounds?
The patent landscape for bicyclic heteroaryl compounds targeting neurological diseases is moderately competitive. Several companies and research institutions are actively developing therapeutics within this space, utilizing similar chemical scaffolds or targeting overlapping biological pathways.
-
Key Players:
- Merck Sharp & Dohme Corp.: As the assignee, Merck is the primary entity holding rights to this specific patent and likely has ongoing R&D programs utilizing these compounds.
- Other Major Pharmaceutical Companies: Large pharmaceutical companies with significant neurology divisions (e.g., Pfizer, Novartis, AbbVie, Eli Lilly) frequently patent compounds with similar therapeutic targets. Patent searches reveal ongoing activity in neurodegenerative disease treatments and other neurological disorders.
- Biotechnology Companies: Smaller, specialized biotech firms often focus on novel drug discovery for specific neurological indications, potentially leading to overlapping patent filings or competitive technologies.
- Academic Institutions: Universities and research centers contribute significantly to early-stage drug discovery in neurology, with many patents originating from academic labs.
-
Areas of Overlap:
- Chemical Scaffolds: Competitors may be developing compounds with related but distinct bicyclic heteroaryl structures, or entirely different chemical classes targeting the same biological mechanisms.
- Therapeutic Targets: Patents may focus on compounds that modulate similar neurotransmitter systems, enzyme activities, or signaling pathways implicated in neurological disorders, even if the chemical structures differ significantly.
- Specific Neurological Indications: While Patent 9,770,441 covers a broad range of neurological diseases, competitors may hold patents focused on a narrower subset of these diseases with specific therapeutic approaches.
What Are the Potential Business Implications?
The existence and scope of Patent 9,770,441 have significant implications for R&D strategy, investment decisions, and market entry for any party operating in the neurological therapeutics space.
- Freedom to Operate (FTO): Companies developing neurological drugs, particularly those involving bicyclic heteroaryl compounds, must conduct thorough FTO analyses to ensure their products do not infringe on the claims of Patent 9,770,441 or related patents.
- Licensing Opportunities: For Merck, the patent represents a potential asset for licensing to other entities for specific indications or geographies, generating revenue without direct commercialization. For other companies, it presents a potential licensing-in opportunity if they wish to utilize these compounds.
- R&D Investment: The patent informs R&D investment by highlighting areas where intellectual property protection is already established. This may lead companies to focus on:
- Developing compounds with significantly different chemical structures or mechanisms of action.
- Targeting different stages or subtypes of neurological diseases.
- Developing next-generation therapies that may circumvent existing patents.
- Generic Competition: As the patent expiration date approaches (November 12, 2034), generic manufacturers will begin to plan for market entry. The strength and breadth of the patent's claims will influence the ease and timeline for generic development.
- Market Exclusivity: The patent grants Merck exclusivity for the claimed compounds and methods until its expiration, providing a significant commercial advantage for any approved products derived from this patent.
Key Takeaways
- U.S. Patent 9,770,441 protects a class of bicyclic heteroaryl compounds and their use in treating neurological diseases.
- The patent's claims cover the compounds, pharmaceutical compositions, and broad methods of treatment for various neurological conditions.
- Merck Sharp & Dohme Corp. is the assignee, with its inventors listed as key contributors.
- The patent is valid until November 12, 2034, providing a period of market exclusivity.
- The competitive landscape is characterized by moderate activity from other pharmaceutical companies and biotech firms focusing on similar chemical scaffolds and therapeutic targets in neurology.
- Companies must conduct Freedom to Operate analyses and consider licensing or alternative R&D strategies in light of this patent.
Frequently Asked Questions
1. Does Patent 9,770,441 cover all compounds used to treat neurological diseases?
No, Patent 9,770,441 specifically covers a defined class of bicyclic heteroaryl compounds and their therapeutic uses. It does not encompass all compounds or all methods for treating neurological diseases.
2. What is the significance of the "Formula (I)" in the patent claims?
"Formula (I)" is a generalized chemical structure provided in the patent that defines the core bicyclic heteroaryl scaffold and the possible variations through substituent groups. It serves to broadly define the scope of chemical entities covered by the patent.
3. Can a generic company start developing a drug for a disease covered by Patent 9,770,441 before it expires?
A generic company can initiate research and development activities, including formulation and clinical trial design, before patent expiration. However, they cannot launch a product that infringes on the patent's claims until the patent has expired or has been invalidated.
4. How does the patent define "a therapeutically effective amount"?
The patent typically defines "a therapeutically effective amount" in the context of its experimental data. This refers to the quantity of the compound administered that is sufficient to produce a desired therapeutic effect in a subject, such as reducing disease symptoms or slowing disease progression, without causing unacceptable toxicity.
5. Are there any known infringements or legal challenges against Patent 9,770,441?
As of the last review, there are no readily available public records indicating active or concluded legal challenges or confirmed infringements specifically against U.S. Patent 9,770,441. However, ongoing monitoring of patent litigation databases is recommended for the most current information.
Citations
[1] United States Patent 9,770,441 B2. (2017). Compositions and methods for treating or preventing neurological disease. Inventors: Smith, G. M., Lillie, J. W., Blake, C. R., Bridges, P. S., Grabowski, E. J., Jane, D. E., Jones, D. L., & McDonald, E. L. Assignee: Merck Sharp & Dohme Corp. Filed: November 12, 2014. Granted: September 26, 2017. Retrieved from USPTO Patent Full-Text and Image Database.
More… ↓
⤷ Start Trial
|
